GlassScriptPhysician profile
Michael A Greenberg
NPI 1891788105
$2,314.45
in general payments reported to CMS, 2019-2025
24 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $12.18 · 2021: $22.56 · 2022: $120 · 2023: $678 · 2024: $875 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.19 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.30 | 2023-2024 | |
| Dermavant Sciences, INC. | $206.38 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $165.32 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $155.68 | 2023-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $146.75 | 2019-2024 | Adbry |
| Genzyme Corporation | $144.72 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $144.11 | 2020-2024 | Ilumya, Winlevi |
| Mayne Pharma Commercial LLC | $128.78 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $128.42 | 2023-2025 | Ycanth |
| Arcutis Biotherapeutics, INC. | $127.89 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $104.08 | 2019 | |
| Janssen Biotech, INC. | $81.14 | 2024-2025 | Tremfya |
| Amgen INC. | $80.85 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $55.89 | 2023-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $54.22 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.76 | 2023-2025 | |
| Ucb, INC. | $40.60 | 2025 | Bimzelx |
| Biofrontera INC. | $38.17 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $37.98 | 2025 | Vtama, Nexplanon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.17 | 2024 | Spevigo |
| Lilly USA, LLC | $31.96 | 2023-2024 | Taltz, Ebglyss, Olumiant |
| Nobelpharma America, LLC | $31.03 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.03 | 2024 | Sotyktu |
| Helsinn Therapeutics (U.S.), INC. | $13.22 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.